RT Journal Article
T1 Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial
A1 Raggi, Paolo
A1 Bellasi, Antonio
A1 Sinha, Smeeta
A1 Bover, Jordi
A1 Rodriguez, Mariano
A1 Ketteler, Markus
A1 Bushinsky, David A.
A1 Garg, Rekha
A1 Perelló, Joan
A1 Gold, Alex
A1 Chertow, Glenn M.
K1 Coronary calcification
K1 Vascular calcification
K1 Hemodialysis
K1 Calcificación vascular
K1 Diálisis renal
K1 Enfermedades Renales
K1 SNF472
AB IntroductionCoronary artery calcium (CAC) is highly prevalent and linked with poor outcomes in patients receiving maintenance hemodialysis, and its reduction may improve patient prognosis. SNF472, a selective inhibitor of hydroxyapatite crystallization, slows CAC progression in patients receiving maintenance hemodialysis. In this analysis, we assessed the efficacy of SNF472 in prespecified patient subgroups.MethodsIn a randomized clinical trial SNF472 300 mg, SNF472 600 mg, or placebo were infused thrice weekly in 91, 92, and 91 patients receiving maintenance hemodialysis and with CAC at baseline, respectively. In prespecified subanalyses, the percent change in CAC volume score (CACvs) from baseline to week 52 in modified intention-to-treat (mITT) and per-protocol (PP) populations was calculated in the following subgroups: age, sex, diabetes mellitus, dialysis vintage, prior atherosclerotic cardiovascular disease, baseline use of non-calcium and calcium-based phosphate binders, calcimimetics, activated vitamin D, warfarin, and statins.ResultsIn the main trial, SNF472 significantly reduced CACvs progression compared with placebo (11% versus 20% mITT analyses; P = 0.016; 8% vs. 24% PP analyses; P < 0.001). Treatment differences for CACvs progression were similar across all subgroups, and all interaction P values were non-significant in mITT and PP analyses.ConclusionsSNF472 treatment for 52 weeks reduced CACvs progression compared with placebo in a broad range of patients receiving maintenance hemodialysis. Future studies will determine the impact of SNF472 on cardiovascular events in this population.
PB International Society of Nephrology. Published by Elsevier Inc.
YR 2020
FD 2020-11-04
LK http://hdl.handle.net/10668/3550
UL http://hdl.handle.net/10668/3550
LA en
NO Raggi P, Bellasi A, Sinha S, Bover J, Rodriguez M, Ketteler M, et al. Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial. Kidney Int Rep. 2020 Nov 4;5(12):2178-2182
DS RISalud
RD Apr 11, 2025